FGAM
ALXN

Financial Gravity Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Financial Gravity Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11
Closed -$184K – 1029
2021
Q2 		$184K Buy
+11
New +$1.89K 0.07% 205
2020
Q4 		$10K Buy
+66
New +$8.48K 0.01% 182
2019
Q4 		$108K Sell
721
-365
-34% -$39K 0.07% 291
2019
Q3 		$106K Sell
1,086
-244
-18% -$27.5K 0.09% 197
2019
Q2 		$174K Sell
1,330
-282
-17% -$36.3K 0.14% 159
2019
Q1 		$218K Buy
+1,612
New +$200K 0.18% 124
2018
Q3 		$215K Buy
1,919
+297
+18% +$37.3K 0.23% 103
2018
Q2 		$193K Sell
1,622
-223
-12% -$26.1K 0.18% 122
2018
Q1 		$211K Buy
+1,845
New +$221K 0.22% 85

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Financial Gravity Asset Management's ALXN Position: Q3 2021 in Review

Financial Gravity Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11 shares — an estimated $184K sold.

Financial Gravity Asset Management first reported a position in ALXN in Q1 2018 and held it in 9 quarters. The position peaked at $218K in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Financial Gravity Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Financial Gravity Asset Management sold 11 Alexion Pharmaceuticals shares in Q3 2021, an estimated $184K.
  • Financial Gravity Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 9 quarters.
  • Financial Gravity Asset Management's Alexion Pharmaceuticals position peaked at $218K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Financial Gravity Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.